rheumatoid arthritis
Lipum recruits new CMO: "I have been following their research for a while and am impressed"
Lipum strengthens the management team with Peter Hovstadius as new Chief Medical Officer ahead of the continued clinical development of SOL-116 for...
Lipum's CEO summarizes the first half of the year – continued positive study data
Lipum's report for the first half of 2024 highlights the...
Issuance to realize new clinical advances for Cyxone
Cyxone wants to explore the great potential it sees...
Cyxone's CEO: "Significantly lower risk in project development"
Cyxone recently updated its development plan for rabeximod and...
Flerie Invest continues to support Lipum
Flerie Invest is Lipum's largest shareholder and holds...
Lipum approaches milestone in the fight against inflammatory diseases
The biopharmaceutical company Lipum is in the final phase of...
Lipum's CEO: "We act quickly and smartly without compromising on quality"
Today begins the subscription period for Lipum's rights issue, which can...
Cyxone comments on clinical collaboration in the UK
Cyxone has entered into a research collaboration with a recognized...
Cyxone's CEO gives a status update
Cyxone recently reached a milestone in its project...
Cyxone's CEO on plans for 2024
Cyxone's CEO Carl-Magnus Högerkorp is interviewed in BioStock's studio...
Ola Sandborgh takes over as CEO of Lipum
Lipum has appointed Ola Sandborgh as new CEO...
New CMO strengthens Lipum ahead of continued clinical development
Lipum is in the final stages of clinical...